NCT04743765 HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
| NCT ID | NCT04743765 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Population Health Research Institute |
| Condition | Hip Fractures |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,100 participants |
| Start Date | 2021-11-22 |
| Primary Completion | 2027-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,100 participants in total. It began in 2021-11-22 with a primary completion date of 2027-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.
Eligibility Criteria
Inclusion Criteria: 1. age ≥45 years; 2. diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery; 3. troponin elevation ( at least one troponin measurement above the upper limit of normal occurring from the time of hip fracture to the time of randomization); and 4. informed consent. Exclusion Criteria: 1. taking a therapeutic dose of an anticoagulant for which no reversing agent is available and the anesthesiologist or surgeon believe surgery within 6 hours of eligibility criteria met would not be safe; 2. patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT); 3. patients with peri-prosthetic fracture, open fracture or bilateral fractures; 4. patients requiring an emergency surgery for another reason (e.g., subdural hematoma); 5. patients with acute myocardial infarction deemed to be clinically unstable, with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock; 6. patients refusing consent; or 7. patients previously enrolled in HIP ATTACK-2.
Contact & Investigator
Flavia Borges, M.D
PRINCIPAL INVESTIGATOR
Population Health Research Institute
Frequently Asked Questions
Who can join the NCT04743765 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, studying Hip Fractures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04743765 currently recruiting?
Yes, NCT04743765 is actively recruiting participants. Contact the research team at valerie.harvey@phri.ca for enrollment information.
Where is the NCT04743765 trial being conducted?
This trial is being conducted at Chandler, United States, Davis, United States, New Haven, United States, Atlanta, United States and 11 additional locations.
Who is sponsoring the NCT04743765 clinical trial?
NCT04743765 is sponsored by Population Health Research Institute. The principal investigator is Flavia Borges, M.D at Population Health Research Institute. The trial plans to enroll 1,100 participants.